Q BioMed, Inc. (OTCQB: QBIO) operates as a biomedical company, which engages in licensing, acquisition, and provider of medical resources to other healthcare companies. Shares of Q BioMed, Inc. are down 23%, during early morning trading on Thursday, January 5, 2017. Over the past three months, the biomedical company has seen average daily volume of 86,837 shares. However, nearly 157,550 shares or dollar volume of $1.3 million, has already exchanged hands early Thursday.

Shares of Q BioMed, Inc. are under pressure Thursday, after the company announced it has been tapped to present at the 9th Annual Biotech Showcase conference in San Francisco, California. The conference will take place January 9-11, 2017 and will be held at the Hilton Union Square. The massive healthcare event brings many executives from science companies from around the world, to discuss the status of the business, the industry, and healthcare. Here is the full press release detailing of the upcoming presentation:

Q BioMed, Inc. Press Release:

NEW YORK, January 5, 2017 /PRNewswire/ –Q BioMed, Inc. (OTCQB: QBIO), a biotechnology acceleration and development company will present at the  9th Annual Biotech Showcase™ 2017 being held January 9-11, 2017 at the Hilton San Francisco Union Square, California. Taking place during one of the industry’s largest annual healthcare investor conferences, this investor and partnering conference attracts pharmaceutical executives from around the world focused on investment and business development opportunities in the life sciences industry.

Conference Presentation Details:

Presenter: Denis Corin – CEO

Where: Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102

When: Tuesday, January 10, 2017

Time: 8:00 AM

Room: Room 3 – Ballroom Level

Webcast: https://event.webcasts.com/viewer/event.jsp?ei=1130761 live and replay 2hr after the event.

Conference Website:  Biotech Showcase 2017

Q BioMed management will host one-on-one meetings with investors at the conference between January 9-11, 2017. To meet with us, please submit a meeting request via the PartneringOne scheduling system.

In addition we provide this update to those unable to attend.

2016 was essentially our inaugural year, being our first full calendar year pursuing innovative opportunities in the biotechnology space. It was a very busy year as the Company established itself in the space and commenced its effort to find innovative technologies and management teams with inherent, yet unrealized, value. By adding strategic resources to accelerate the development of those technologies, we hope to realize that value.

We closed 2016 with two pipeline technologies under the ‘Q’ umbrella; essentially bookends of the multi-asset business model we are building. One early stage, opportunity in the highly sought after glaucoma space and one FDA approved, drug for bone cancer palliation. In addition, we recently secured the funding to allow us to execute on the near term milestones to advance our business.

Over the course of the next several months we will continue performing due diligence on additional attractive assets with the goal of adding one or more to our pipeline in calendar 2017.

Review of Strontium Chloride 89 Injection (SR89):

In September 2016 we licensed an FDA approved drug that provides relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. It has been proven to provide a long-term effect resulting in cancer pain relief and enhanced quality of life.

Revenue from sales of our non-narcotic pain palliative drug will be a major catalyst for Q BioMed and we look forward to providing additional guidance on the timing of this in the near future.

Review of Man-01 our glaucoma asset licensed from Mannin Research Inc:

The MAN-01 asset for treatment of Primary Open Angle Glaucoma (POAG), is continuing to progress in its pre-clinical lead candidate optimization of a small molecule for a topical application.

Mannin will continue with preclinical research and development activities for 2017 before progressing into IND enabling studies, expected in 2018 to be followed by first in human proof-of-concept clinical trials.

Our efforts in establishing research and development partnerships with commercial partners, as well as government organizations to provide technical and financial support for the development of MAN-01 for POAG is ongoing. To this end, Mannin is continuing strategic partnership discussions with companies and technologies that will strengthen its intellectual property portfolio in the Tie2/TEK mechanism of action market.

Thank you for your interest in Q BioMed and we hope you continue following our progress.

Happy New Year and may it bring you good health, happiness and prosperity!

Please visit our website http://www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress. http://www.qbiomed.com

About Q BioMed, Inc.

Q BioMed Inc.”Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Add a Comment to this Post